These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 25282870)

  • 1. COPD costs to approach $50B per year in 2020.
    Manag Care; 2014 Sep; 23(9):57. PubMed ID: 25282870
    [No Abstract]   [Full Text] [Related]  

  • 2. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
    Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
    Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.
    Toy EL; Beaulieu NU; McHale JM; Welland TR; Plauschinat CA; Swensen A; Duh MS
    Respir Med; 2011 Mar; 105(3):435-41. PubMed ID: 20880687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with chronic obstructive pulmonary disease.
    Stuart BC; Simoni-Wastila L; Zuckerman IH; Davidoff A; Shaffer T; Yang HW; Qian J; Dalal AA; Mapel DW; Bryant-Comstock L
    Am J Geriatr Pharmacother; 2010 Oct; 8(5):441-53. PubMed ID: 21335297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
    Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS
    COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
    Chiang CH
    Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Estimation of direct medical costs of chronic obstructive pulmonary disease over 12 months].
    Stâmbu I; Stoicescu IP
    Pneumologia; 2013; 62(2):86-92. PubMed ID: 23894789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost impact of COPD in Japan: opportunities and challenges?
    Nishimura S; Zaher C
    Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
    Jahnz-Rózyk K; Targowski T; From S
    Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991.
    Jacobson L; Hertzman P; Löfdahl CG; Skoogh BE; Lindgren B
    Respir Med; 2000 Mar; 94(3):247-55. PubMed ID: 10783936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of COPD exacerbations in the emergency department and inpatient setting.
    Dalal AA; Shah M; D'Souza AO; Rane P
    Respir Med; 2011 Mar; 105(3):454-60. PubMed ID: 20869226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations].
    Jahnz-Rózyk K; Targowski T; From S; Płusa T
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():91-4. PubMed ID: 15524028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct medical costs of COPD--an excess cost approach based on two population-based studies.
    Menn P; Heinrich J; Huber RM; Jörres RA; John J; Karrasch S; Peters A; Schulz H; Holle R;
    Respir Med; 2012 Apr; 106(4):540-8. PubMed ID: 22100535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic obstructive pulmonary disease involves substantial health-care service and social benefit costs.
    Jensen MB; Fenger-Grøn M; Fonager K; Omland Ø; Vinding AL; Hansen JG
    Dan Med J; 2013 Jan; 60(1):A4557. PubMed ID: 23340185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Projections of future resource use and the costs of asthma and COPD in the Netherlands].
    Hoogendoorn M; Feenstra TL; Rutten-van Mölken MP
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1243-50. PubMed ID: 16796176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [What are the socio-economic consequences of acute COPD exacerbations?].
    Bourdin A; Molinari N
    Rev Mal Respir; 2017 Apr; 34(4):338-342. PubMed ID: 28476415
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic evaluation of a disease management program for chronic obstructive pulmonary disease.
    Dewan NA; Rice KL; Caldwell M; Hilleman DE
    COPD; 2011 Jun; 8(3):153-9. PubMed ID: 21513435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking health care costs: trends stabilize but remain high in 2002.
    Data Bull (Cent Stud Health Syst Change); 2003 Jun; (25):1-2. PubMed ID: 12807135
    [No Abstract]   [Full Text] [Related]  

  • 20. The health and economic burden of chronic diseases in North Carolina.
    Easley C; Petersen R; Holmes M
    N C Med J; 2010; 71(1):92-5. PubMed ID: 20369687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.